Étiquette : sclerose en plaques

Cannabinoid-based Medications for Pain Raymond M. St. Marie, Raphael J. Leo, 2021

Cannabinoid-based Medications for Pain Raymond M. St. Marie, MD; Raphael J. Leo, MA, MD Current Psychiatry, 2021, 20(5), 21-33. Abstract and Introduction Introduction Against the backdrop of an increasing opioid use epidemic and a marked acceleration of prescription opioid–related deaths,[1,2] there has been an impetus to explore the usefulness of alternative and co-analgesic agents to assist patients with chronic pain. Preclinical studies employing animal-based models of human pain syndromes have demonstrated that cannabis and chemicals derived from cannabis extracts may mitigate several pain conditions.[3] Because there are significant comorbidities between psychiatric disorders and chronic pain, psychiatrists are likely to care for patients with chronic pain. As [...]

Lire la suite

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis, Sara Arias et al., 2021

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis Sara Arias, Marta Leon, Diego Jaimes and Rosa-Helena Bustos Pharmaceuticals, 2021, 14, 78, 1-13. Doi :10.3390/ph14020078   Abstract : Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment [...]

Lire la suite

Cannabis Misconceptions Still Common Among MS Clinicians, Nancy Melville, Medscape.com, 2020

Cannabis Misconceptions Still Common Among MS Clinicians Nancy Melville June 05, 2020 https://www.medscape.com/viewarticle/931872?nlid=135873_425&src=WNL_mdplsfeat_200609_mscpedit_psyc&uac=292598PZ&spon=12&impID=2413707&faf=1   Despite the ever-increasing acceptance of medical cannabis and its notably common use in patients with multiple sclerosis (MS), clinicians treating those patients still may be poorly informed about risks, benefits, regulations, and proper uses, experts say. "There is evidence of a 'clinical void,' with clinicians on one side and people with MS and other conditions on the other that doesn't usually exist regarding therapies that people with MS are using," said Allen C. Bowling, MD, PhD, director of the NeuroHealth Institute and clinical professor of neurology at the University of Colorado, in Aurora. His [...]

Lire la suite

Related Symptoms in People With Multiple Sclerosis : Results From a Retrospective Multicenter Study, Francesco Patti et al., 2020

Related Symptoms in People With Multiple Sclerosis : Results From a Retrospective Multicenter Study Francesco Patti, Clara Grazia Chisari, Claudio Solaro,  Maria Donata Benedetti , Eliana Berra , Assunta Bianco, Roberto Bruno Bossio, Fabio Buttari, Letizia Castelli, Paola Cavalla , Raffaella Cerqua, Gianfranco Costantino, Claudio Gasperini, Angelica Guareschi, Domenico Ippolito, Roberta Lanzillo, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Margherita Russo, Francesco Saccà, Giovanna Salamone, Elisabetta Signoriello, Gabriella Spinicci, Daniele Spitaleri, Eleonora Tavazzi, Maria Trotta, Mauro Zaffaroni, Mario Zappia, SA.FE. group Doi : 10.1007/s10072-020-04413-6 Abstract Introduction : The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed [...]

Lire la suite

The Broad Concept of “Spasticity- Plus Syndrome” in Multiple Sclerosis : A Possible New Concept in the Management of Multiple Sclerosis Symptoms, Óscar Fernández et al., 2020

The Broad Concept of “Spasticity- Plus Syndrome” in Multiple Sclerosis : A Possible New Concept in the Management of Multiple Sclerosis Symptoms Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto and Lluis Ramió Frontiers in Neurology , 2020 | Volume 11 | Article 152 doi : 10.3389/fneur.2020.00152   Multiple sclerosis (MS) pathology progressively affects multiple central nervous system (CNS) areas. Due to this fact, MS produces a wide array of symptoms. Symptomatic therapy of one MS symptom can cause or worsen other unwanted symptoms (anticholinergics used for bladder dysfunction produce impairment of cognition, many MS drugs produce erectile dysfunction, etc.). Appropriate symptomatic [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoïdes en Neurologie, Docteur Christian SUEUR, GRECC, avril 2020

Bibliographie Cannabis et Cannabinoïdes en Neurologie   Docteur Christian SUEUR, GRECC, avril 2020.     Cannabinoïdes et Sclérose en Plaque, p 4. Cannabinoïdes et Migraines, p 7. Cannabinoïdes et maladies neurodégénératives, p 8. Cannabinoïdes et Maladie de Parkinson, p 10. Cannabinoïdes et Maladie de Huntington, p 11. Cannabinoïdes et Maladie d’Alzheimer, p 12.    

Lire la suite

Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis, Tibor M. Brunt et al., 2014

Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis Tibor M. Brunt, Marianne van Genugten, Kathrin Honer-Snoeken, Marco J. van de Velde, and Raymond J.M. Niesink Journal of Clinical Psychopharmacoly, 2014, 34, 344Y349 Doi : 10.1097/JCP.0000000000000129   Abstract : In The Netherlands, pharmaceutical-grade cultivated cannabis is distributed for medicinal purposes as commissioned by the Ministry of Health. Few studies have thus far described its therapeutic efficacy or subjective (adverse) effects in patients. The aims of this study are to assess the therapeutic satisfaction within a group of patients using prescribed pharmaceutical-grade cannabis and to compare the subjective effects among the available strains with special [...]

Lire la suite

The cannabinoids : An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection, R. Mechoulam & L. Hanus, 2001

The cannabinoids : An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection R. Mechoulam PhD, L Hanušs PhD Pain Research Management, 2001, 6, (2), 67-73. Doi : 10.1155/2001/183057   The present paper describes the historical use of cannabis, starting with its use in Assyria and China. Recent advances in the understanding of the molecular basis of cannabis action are explained, including the identification of the cannabinoid receptors CB1 and CB2, as well as the isolation of endogenous cannabinoids from the brain and periphery. The use of delta9-tetrahydrocannabinol as an antivomiting and antinausea drug for cancer [...]

Lire la suite

Medical cannabis trial will target 20,000 UK patients, Jamie Doward and Lily Gordon Brown, The Guardian, 3 novembre 2019.

Medical cannabis trial will target 20,000 UK patients Jamie Doward and Lily Gordon Brown The GUARDIAN, Published on Sun 3 Nov 2019 https://www.theguardian.com/society/2019/nov/03/medical-cannabis-uk-clinical-trial-patients-nhs   Project backed by Royal College of Psychiatrists aims to be largest on drug’s use in Europe • Medical cannabis: Why are doctors still not prescribing it? Tilray medicinal cannabis growing facility in Canada. Photograph: Tilray Up to 20,000 patients in the UK are to be given medical cannabis over a two-year period in an initiative that aims to create the largest body of evidence on the drug in Europe. The move, to be unveiled on Thursday, is [...]

Lire la suite

Endocannabinoid System in Neurological Disorders, Roberta Ranieri et al., 2016

Endocannabinoid System in Neurological Disorders (Endocannabinoid System and Neurodegeneration) Roberta Ranieri, Chiara Laezza, Maurizio Bifulco, Daniela Marasco and Anna Maria Malfitano Recent Patents on CNS Drug Discovery, 2015, Vol. 10, No. 2, 24 p. Abstract : Background : Several studies support the evidence that the endocannabinoid system and cannabimimetic drugs might have therapeutic potential in numerous pathologies. These pathologies range from neurological disorders, atherosclerosis, stroke, cancer to obesity/metabolic syndrome and others. Methods : In this paper we review the endocannabinoid system signaling and its alteration in neurodegenerative disorders like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease and discuss the main findings about the use [...]

Lire la suite